Praxis Q3 2022 net loss $43.9M; cash $123.7M; PRAX-944 top-line results expected 1Q23

Praxis Precision Medicines, Inc.

2022-Q3 EPS reported -$3.79

Net loss $43.9M vs $44.7M YoY; R&D expenses $30.4M down from $33.1M.
Cash and investments $123.7M, down from $275.9M at year-end 2021; runway into 1Q24.
PRAX-944 Phase 2b Essential1 top-line results for essential tremor expected 1Q23; screening to complete mid-Nov 2022.
PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; initial dose cohort results expected 2023.
PRAX-114 Phase 2 Acapella study in MDD not statistically significant; no further development planned.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Praxis Precision Medicines, Inc. reported financial results for the third quarter of 2022.

Period: the third quarter of 2022
Result: reported results

Exact text from the filing

On November 9, 2022, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Praxis Precision Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001689548-22-000124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.